Effects of empagliflozin on functional capacity, left ventricular (LV) filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial
Authors' conclusion
In diabetic patients with HFpEF, empagliflozin treatment improved exercise capacity, which appeared to be the result of favourable effects on LV diastolic dysfunction and key cardiac reserves: LV diastolic, LA reservoir and contractile, and chronotropic. These haemodynamic mechanisms may underline the benefits of SGLT2 inhibitors in large-scale HFpEF trials.
Study context
- Population
- Patients with T2D and stable heart failure (HF) (NYHA class II–III), LV ejection fraction ≥ 50%, and increased LV filling pressure at rest and/or during exercise (echocardiography)
- Participants
- 70 patients
- Comparison
- Empagliflozin vs control
- Empagliflozinn = 35
- Controln = 35reference
- Primary endpoint
- Change in the 6-min walk test distance (6MWD)
- Follow-up
- Baseline to 6 months
Methodological detailsprospective, single-centre, open-label
- Prospective
- Single-centre
- Open-label
Primary result
As reported in the abstract
Change in 6MWD · 6 months
- 6MWD significantly increased with empagliflozin vs control
- Empagliflozin vs Control: P < 0.05 for all
Secondary outcomes
| Outcome | P value |
|---|---|
| LA volume index and E/e' ratio at rest and during exercise · 6 monthsDecreased with empagliflozin vs control | P < 0.05 for all |
| LV diastolic, LA reservoir and contractile, and chronotropic reserves · 6 monthsImproved with empagliflozin vs control | P < 0.05 for all |
| NT-proBNP and ST2 blood levels · 6 monthsImproved with empagliflozin vs control | P < 0.05 for both |
Original publication
Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial. Cardiovasc Diabetol. Published 9 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →